Lexaria Bioscience Corp. (NASDAQ:LEXX) went up by 57.25% from its latest closing price compared to the recent 1-year high of $12.90. The company’s stock price has collected -3.37% of loss in the last five trading sessions. Press Release reported 2 hours ago that Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
Is It Worth Investing in Lexaria Bioscience Corp. (NASDAQ :LEXX) Right Now?
Plus, the 36-month beta value for LEXX is at 1.57. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Lexaria Bioscience Corp. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $36.00. LEXX currently public float of 4.25M and currently shorts hold a 10.64% ratio of that float. Today, the average trading volume of LEXX was 954.56K shares.
LEXX’s Market Performance
LEXX stocks went down by -3.37% for the week, with a monthly drop of -2.95% and a quarterly performance of 42.95%, while its annual performance rate touched -33.43%. The volatility ratio for the week stands at 5.54% while the volatility levels for the past 30 days are set at 5.02% for Lexaria Bioscience Corp.. The simple moving average for the period of the last 20 days is 52.47% for LEXX stocks with a simple moving average of 64.83% for the last 200 days.
LEXX Trading at 58.97% from the 50-Day Moving Average
After a stumble in the market that brought LEXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.67% of loss for the given period.
Volatility was left at 5.02%, however, over the last 30 days, the volatility rate increased by 5.54%, as shares surge +65.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +76.25% upper at present.
During the last 5 trading sessions, LEXX rose by +64.36%, in comparison to the 20-day moving average, which settled at $7.01. In addition, Lexaria Bioscience Corp. saw -11.89% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LEXX
Current profitability levels for the company are sitting at:
- -1052.29 for the present operating margin
- +44.84 for the gross margin
The net margin for Lexaria Bioscience Corp. stands at -1023.03. The total capital return value is set at -157.79, while invested capital returns managed to touch -156.47. Equity return is now at value -53.80, with -51.40 for asset returns.
Based on Lexaria Bioscience Corp. (LEXX), the company’s capital structure generated 6.18 points at debt to equity in total, while total debt to capital is 5.82. Total debt to assets is 5.52, with long-term debt to equity ratio resting at 4.75. Finally, the long-term debt to capital ratio is 4.48.
When we switch over and look at the enterprise to sales, we see a ratio of 71.71, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 1.31 and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.53.